Cleveland BioLabs Inc. [NASDAQ: CBLI] gained 19.83% on the last trading session, reaching $6.95 price per share at the time. The company report on April 10, 2021 that SHAREHOLDER ALERT: WeissLaw LLP Reminds MDCA, PTVCA, CBLI, and WIFI Shareholders About Its Ongoing Investigations.
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:.
Cleveland BioLabs Inc. represents 13.28 million in outstanding shares, while the company has a total market value of $109.39 million with the latest information. CBLI stock price has been found in the range of $5.57 to $7.17.
If compared to the average trading volume of 382.19K shares, CBLI reached a trading volume of 1081427 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Cleveland BioLabs Inc. [CBLI]:
Oppenheimer have made an estimate for Cleveland BioLabs Inc. shares, keeping their opinion on the stock as Perform, with their previous recommendation back on January 24, 2014. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Buy. The new note on the price target was released on March 21, 2013, representing the official price target for Cleveland BioLabs Inc. stock. Previously, the target price had yet another raise to $3, while Oppenheimer analysts kept a Outperform rating on CBLI stock.
The Average True Range (ATR) for Cleveland BioLabs Inc. is set at 0.56, with the Price to Sales ratio for CBLI stock in the period of the last 12 months amounting to 364.64.
Trading performance analysis for CBLI stock
Cleveland BioLabs Inc. [CBLI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 19.21. With this latest performance, CBLI shares gained by 16.03% in over the last four-week period, additionally plugging by 231.32% over the last 6 months – not to mention a rise of 339.87% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CBLI stock in for the last two-week period is set at 62.18, with the RSI for the last a single of trading hit 68.19, and the three-weeks RSI is set at 59.23 for Cleveland BioLabs Inc. [CBLI]. The present Moving Average for the last 50 days of trading for this stock 6.14, while it was recorded at 6.12 for the last single week of trading, and 3.61 for the last 200 days.
Cleveland BioLabs Inc. [CBLI]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Cleveland BioLabs Inc. [CBLI] shares currently have an operating margin of -983.70. Cleveland BioLabs Inc.’s Net Margin is presently recorded at -912.16.
Reflecting on the efficiency of the workforce at the company, Cleveland BioLabs Inc. [CBLI] managed to generate an average of -$399,743 per employee. Receivables Turnover for the company is 1.35 with a Total Asset Turnover recorded at a value of 0.12.Cleveland BioLabs Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.60 and a Current Ratio set at 7.60.
An analysis of insider ownership at Cleveland BioLabs Inc. [CBLI]
There are presently around $4 million, or 4.00% of CBLI stock, in the hands of institutional investors. The top three institutional holders of CBLI stocks are: ARMISTICE CAPITAL, LLC with ownership of 320,053, which is approximately New of the company’s market cap and around 50.26% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 165,651 shares of the stock with an approximate value of $0.96 million in CBLI stocks shares; and VANGUARD GROUP INC, currently with $0.3 million in CBLI stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Cleveland BioLabs Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 4 institutional holders increased their position in Cleveland BioLabs Inc. [NASDAQ:CBLI] by around 348,258 shares. Additionally, 5 investors decreased positions by around 70,751 shares, while 13 investors held positions by with 203,918 shares. The mentioned changes placed institutional holdings at 622,927 shares, according to the latest SEC report filing. CBLI stock had 4 new institutional investments in for a total of 348,258 shares, while 2 institutional investors sold positions of 26,918 shares during the same period.